

Evaluation of BAALC gene expression in normal cytogenetic acute myeloid leukemia patients in north-east of Iran

Mojgan Amirpour¹, Hossein Ayatollahi², Maryam Sheikhi³, Somaye Azarkerdar⁴
Seyyede Fatemeh Shams^{*5}

Received: 8 April 2016

Accepted: 28 May 2016

Published: 27 September 2016

Abstract

Background: Acute myeloid leukemia (AML) is known as one of the most common leukemia among adults. Environmental and different genetic factors affect disease process, prognosis and treatment. Among different genetic factors NPM1, FLT3, MLL and BAALC genes are the most effective on patient's survival rate. The aim of this study was to assess amount of BAALC gene expression in AML patients, and its relation to survival rate.

Methods: In this case-control study, from all 94 individuals referred to Ghaem Medical Center during 2012-2015, 47 cases were normal cytogenetic AML and others were healthy individuals that were studied as control group. Real-time PCR method was applied for gene expression evaluation. Other information of patients was extracted from medical documents. SPSS v.21 was used for data processing.

Results: Mean age of studied cases was 31.50 years. The most of BAALC gene expression was seen in M1 and M2 subtypes, and the less was in M5. A significant relation was found between amount of gene expression and patient's survival rate.

Conclusion: BAALC gene expression was increased significantly in AML cases. BAALC expression had reverse relation with patients' survival rate in North-East of Iran.

Keywords: Acute myeloid leukemia, Survival rate, Prognosisampus.

Cite this article as: Amirpour M, Ayatollahi H, Sheikhi M, Azarkerdar S, Shams SF. Evaluation of BAALC gene expression in normal cytogenetic acute myeloid leukemia patients in north-east of Iran. *Med J Islam Repub Iran* 2016 (27 September). Vol. 30:418.

Introduction

Acute myeloid leukemia (AML) is a malignant clonal disorder of immature myeloid hematopoietic cells that is the most common type of acute leukemia among adults. This malignancy composes 80% of adult leukemia. Reported mean age of AML patients is 60. Some factors such as viruses, radiation, chemotherapy, benzene exposure and smoking increase risk of AML (1-4). Also, agents such as age, molecular and genetic changes such as FLT3, NPM1, MLL disorders and hematologic indices are important prognostic factors in AML process (5-11). In addition to mentioned genes,

brain and acute leukemia-cytoplasmic (BAALC) gene is an important factor in treatment and prognosis determination (12-16).

BAALC gene is located in 8q23.3 position. It is 90kb in length which has 8 exons (17, 18). Overexpression of BAALC gene is reported in AML subjects with trisomy 8 abnormalities in gene expression studies (12). It is a new marker in hematopoietic progenitor cells, which its effects are indeterminate on cellular mechanism (12,13,17-19). Different studies emphasis on gene expression level impression on different physiologic and pathologic circumstances

¹. MSc student of Hematology and Blood Banking, Mashhad University of Medical Sciences, Mashhad, Iran. amirpourm1@mums.ac.ir

². MD, Associate Professor of Hematopathology, Cancer Molecular Pathology Research Center, Department of Hematology and Blood Bank, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. ayatollahihossein@yahoo.com

³. MSc, Cancer Molecular Pathology Research Center, Department of Hematology and Blood Bank, Mashhad University of Medical Sciences, Mashhad, Iran. Iran.msheikhi2@yahoo.com

⁴. MSc Student of Hematology and Blood Banking, Mashhad University of Medical Sciences, Mashhad, Iran. azarkerdars921@mums.ac.ir

⁵. (Corresponding author) MSc, Cancer Molecular Pathology Research Center, Department of Hematology and Blood Bank, Mashhad University of Medical Sciences, Mashhad, Iran. shams8869@yahoo.com

prognosis. Generally, BAALC expression is a suitable prognostic marker which can be used to assign survival rate in normal cytogenetic AML (CN-AML) individuals (12,14).

No study was found in AML patients in mentioned field in North East of Iran, thus, the aim of this study was to define amount of gene expression and frequency of up and down regulation of BAALC gene, and to determine the survival rate of affected patients.

Methods

In this case-control study, 94 individuals referred to molecular pathology research center of Ghaem Hospital in Mashhad city during 2012-2015 were recruited in 2016. From all, 47 cases were normal cytogenetic AML and others were healthy individuals that were studied as control group. All patients were categorized based on French-American-British (FAB) criteria. Patients' age and sex and hematological indices were achieved from medical files. Extracted information included peripheral blood and bone marrow blast count, red and white blood cells and platelets, mean cell volume (MCV), mean cell hemoglobin (MCH), mean cell hemoglobin concentration (MCHC) and clinical signs including splenomegaly, hepatomegaly, and lymphadenopathy and bleeding protests. Three years survival rate were determined by phone call to patients family. It is necessary to mention that this research was approved by Ethics Committee of Mashhad University of Medical Sciences, code 839.

Peripheral blood samples of all studied cases were collected in EDTA container tubes. Peripheral blood mononuclear cell were separated by Ficoll gradient centrifugation method and Sigma Aldrich kit (Sigma Aldrich Company, Saint Louis, MO, USA). In the following RNA extraction was done by Tri-pure solution (Tri-pure kit, Cat No. 11 667 165 001, made by Germany). Mentioned tests were applied according to kit instruction.

RevertAid™ H Minus First Strand cDNA

Synthesis Kit (Fermentase company, thermo scientific 100 reactions) was applied for cDNA synthesis. GPI gene control primers were evaluated for cDNA qualification confirmation, by PCR method; the results were checked on agarose gel. Qualification of synthesized cDNA was evaluated by nano drop instrument (thermo scientific 2000, made in Finland) in 260nm wavelength.

All samples' concentration was > 450ng/μL. Studied genes sequences were obtained from Baldus .et al study (13). To determine Primers specificity and evaluation of sequence homology BLAST software were applied which is available in NCBI site. Forward primers for GPI gene were 5'-TCTTCGATGCCAACAAGGAC-3' and 5'-CTTTTGCAGGCATTCTCTTAGCA-3' for BAALC gene. The Reverse primers was 5'-GCATCACGTCCTCCGTCAC-3' for GPI and 5'-CTTTTGCAGGCATTCTCTTAGCA-3' for BAALC gene. The used probe sequences were 5'-TTCAGCTTGACCCTCAACACCAAC-3' for GPI and 5'-CTCTTTTAGCCTCTGTGGTCTGAAGGCCAT-3' for BAALC.

Real time PCRs were applied in thermo cycler ABI (made in USA). All samples were tested in duplicate. RT-PCR reaction master mix (20μL for each reaction) contained 10μL taq man master mixes, 0.5μL ROX stain, 1μL of each forward and reverse primers (10pm), 1μL taq man probe (5pm), 2μL cDNA , 4.5μL double distilled sterile water .Finally the following temperature patterns were planned in termocycler; 50C° for 2 minutes, 95C° for 15second, 95C° for 15 seconds, and 60C° for 1 minute. The second, third and fourth steps were repeated for 40 times. The amount of gene expression was calculated by ΔCT method. Melting curve analysis was done for products specificity confirmation.

Chi-square, t-test, Kruskal-Wallis and Mann-Whitney tests were applied for analysis based on data distribution (checked using Kolmogorov-Smirnov test), through SPSS v.21. P-value<0.05 was considered

significant.

Results

There were 26 (55.3%) male and 21 (44.7%) female in patient group. Gender distribution of controls was same as cases group. Patients were categorized to child and adult; the first one was ≤ 15 and consisted of 13 (27.5%) and the second was > 15 which consisted of 34 (72.5%) approached subjects. Patients' mean \pm SD age was 31.5 ± 23.72 yrs. The youngest one was 2 yrs and the oldest 77 yrs. Table 1 indicates the patients' frequency based on morphologic subtypes. Most of patients were in M1 (29.78%) and M2 (27.65%) subtypes based on FAB categorization. Mean of peripheral blood and bone marrow blasts were 39.0% and 66.2% in AML cases, respectively. Hematologic and clinical findings of studied cases are mentioned in Table 2. Mean of Hb, HCT and RBC indices were significantly different between the two groups ($p=0.03$), which is justifiable with occurred pancytopenia. In comparison of BAALC gene expression there was no any significant relation between amount of gene expression and clinical and hematological parameters ($p=0.02$). Among hematologic indices, RBC count had significant invert relation with amount of BAALC gene expression; patients' age and sex were related to BAALC expression too ($p>0.05$). Mean of gene expression was 1.20 ± 0.86 in pa-

tients and 1.0 ± 0.00 in controls. Gene evaluation was associated with up regulation in 47% of cases and down regulation in 53% of patients. Survival rate was assessed during 36 months in 47 AML patients and it was 26 months in down regulation subjects and 33 months in up regulation individuals. There was significant relation between up regulation of BAALC and survivability reduction ($p=0.04$).

Discussion

In the recent decades, genomic profile has been used to identify prognostic factors of leukemia. ERG, BAALC, MN1 and WT1 genes are considered as categorization indices based on gene expression patterns; they can be used to distinguish therapeutic intervention and disease process in AML patients (13,20). Although BAALC overexpression mechanism has not been recognized yet, but it is reported in myeloid leukomogenesis. This up regulation prevents myeloid blast differentiation and is associated with poor prognosis in AML and acute lymphoblastic leukemia (ALL) individuals. Different research revealed that BAALC up regulation has been observed in glioblastoma, melanoma and gastrointestinal cancers; they suggested an oncogenic role for BAALC (21).

This gene expression is known as a prognostic and survival rate marker in normal cytogenetic AML cases (12). BAALC up

Table 1. Frequency distribution of morphologic subtypes of AML patients

AML subtypes	Each subtype	Up regulation	Down regulation
M0	2.12 (1)*	2.12 (1)	0
M1	29.78 (14)	57.14 (8)	42.85 (6)
M2	27.65 (13)	53.84 (7)	46.15 (6)
M3	10.63 (5)	0	100 (5)
M4	12.76 (6)	0	100 (6)
M5	10.63 (5)	0	100 (5)
M6	4.25 (2)	50 (1)	50.00 (1)
M7	2.12 (1)	0	100 (1)

*% (n)

Table 2. Hematological findings of studied cases

Variable	Gene expression	Mean \pm SD	p
Blast-Blood	Up regulation	11.1 \pm 51.69	0<.05
	Down regulation	10.4 \pm 31.12	
Blast -BM	Up regulation	3.4 \pm 65.68	0.80
	Down regulation	5.2 \pm 65.77	

regulation was seen in 47.00% of AML group members of this study; Damiani et al research on 175 AML patients by RT-PCR method revealed up regulation in 50% of studied cases, and recommended it as a suitable marker for minimal residual disease (MRD) assignment (15). High BAALC expression was reported in 48.51% of 125 CN-AML individuals of Yoon's study in Korea too (22).

Baldus study on BAALC gene expression and FLT3 mutation in normal cytogenetic AML patients under 60 years found no significant differences between age, sex and bone marrow blast count and amount of expressed BAALC gene, before treatment; he mentioned poor prognosis of BAALC up regulation too; while cited gene overexpression and peripheral blood blasts increment were seen in M1 and M0 subtypes. In current study, BAALC down regulation was obvious in M5b subtype (13). Parts of our findings were supported by Baldus (13) and Weber's (12) studies which expressed that there were no any significant relationships between BAALC expression, gender and hematological parameters (WBC, HB, bone marrow and peripheral blood blasts count).

Yahya et al in their study about prognostic role of BAALC gene in AML patients in Egypt in 2013 represented up regulation in 48.9% of studied cases; while they did not report any relations between BAALC up regulation and clinical parameters. They reported BAALC up regulation in association with patient's survival rate reduction and indicated to its prognostic role (16). We calculated amount of cited gene expression in each morphologic group (based on FAB), the most up regulated cases were M1 and M2; as mentioned before it is reasonable according to blast count in these groups. The most frequent down regulation was seen in M5 subtype. These findings are similar to Baldus et al reported result about normal cytogenetic AML patients under 60; as it mentioned before they observed overexpression of BAALC along with peripheral blood blast increment in

M1 and M0 and down regulation in M5b subtypes. Their findings support our results about poor prognosis of BAALC over expression too (13). Liu et al stated that BAALC overexpression is seen in undifferentiated cells; they found the most up regulation in M0, M1 and M2 categories too, same as our findings (23).

Conclusion

Current study emphasized that BAALC up regulation is increased in AML patients, and it is more common in M1 and M2 subtypes. It is associated with bad prognosis. BAALC regulation mechanism need more studies in AML patients and in normal hematopoiesis.

Acknowledgments

We are very thankful to all personnel of Cancer Molecular Research Center of Mashhad University of Medical Sciences for their technical supports.

References

1. McPherson RA, Pincus MR. HENRY'S Clinical Diagnosis and Management by Laboratory Methods. 22nd ed. Philadelphia: Elsevier Saunders. 2011:1451.
2. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. *Am J Hematol* 2012;87(1):89-99.
3. Hoffman R. hematology: Basic principles and practices .fourth ed: Churchill Livingstone; 2005:1074-75.
4. Campana D, Pui C. Childhood acute lymphoblastic leukemia. In: Hoffbrand V, editor. *Postgraduate Haematology*. 6 ed: Blackwell. 2011:448.
5. Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. *J Hematol Oncol* 2009;2(2):23.
6. Steffen B, Müller-Tidow C, Schwäble J, Berdel WE, Serve H. The molecular pathogenesis of acute myeloid leukemia. *Crit Rev Oncol Hematol* 2005; 56(2):195-221.
7. Hoffbrand AV, Moss PAH, Pettit JE. *Essential Hematology*. 6 ed: Khosravy; 2011:145.
8. Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo

cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. *Blood* 2008;111(3):1552-9.

9. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. *J Clin Oncol* 2008;26(31):5078-87.

10. Andreoli T, Carpenter, Griggs, B. *Essentials of Medicine Cecil*. 17 ed. Tehran: Arjmand. 2007:1669-84.

11. Damm F, Heuser M, Morgan M, Wagner K, Görlich K, Großhennig A, et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. *Blood* 2011;117(17):4561-8.

12. Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C, et al. BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia. *Blood Cancer J* 2014;10(4):e173.

13. Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. *J Clin Oncol* 2006;10(24):790-7.

14. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. *Blood* 2008;111(11):5371-9.

15. Damiani D, Tiribelli M, Franzoni A, Michelutti A, Fabbro D, Cavallin M, et al. BAALC overexpression retains its negative prognostic

role across all cytogenetic risk groups in acute myeloid leukemia patients. *Am J Hematol* 2013; 88(10):848-52.

16. Yahya RS, Sofan MA, Abdelmasseih HM, Saudy N, Sharaf-Eldein MA. Prognostic implication of BAALC gene expression in adult acute myeloid leukemia. *Clin Lab* 2013;59(5-6):621-8.

17. Tanner SM, Austin JL, Leone G, Rush LJ, Plass C, Heinonen K, et al. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. *Proc Natl Acad Sci USA* 2001; 98(24):13901-6.

18. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. *Blood* 2011;118(20): 5593-603.

19. Heuser M, Berg T, Kuchenbauer F, Lai C, Park G, Fung S, et al. Functional role of BAALC in leukemogenesis. *Leukemia* 2011;26(3):532-6.

20. Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1 and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype, and younger than 60 years: a systematic review and meta-analysis. *Ann Hematol* 2014; 93(8):1279-1286.

21. Azizi Z, Rahgozar S, Moafi A, Dabaghi M, Nadimi M. mRNA over expression of BAALC: A novel prognostic factor for pediatric acute lymphoblastic. *Leukemia* 2015;3(3):371-374.

22. Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS, et al. Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia. *Leuk Lymphoma* 2014;55(1):110-120.

23. Xu B, Chen G, Shi P, Guo X, Xiao P, Wang W, et al. shRNA-mediated BAALC knockdown affects proliferation and apoptosis in human acute myeloid leukemia cells. *Hematol* 2012;17(1):35-40.